TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3546949
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CTX) plus BCG treatment
Study: 20012877
Drug: Combined parent
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined parent training and child treatment (PT + CT)
Study: 15961987
Drug: Xenadrine RFA
Normalized name: Xenazine
DrugBank: Tetrabenazine (DB04844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xenadrine RFA (25 mg ephedra alkaloids and 200 mg caffeine)
Study: 12869911
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide aqueous nasal spray (TAA AQ) 220 microg daily
Study: 12869911
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 200 microg daily
Study: 8551406
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg per day oral prednisone for 6 to 12 weeks
Study: 8551406
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg per day oral prednisone for 6 to 12 weeks
Study: 1702493
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (cisplatin-based combination chemotherapy)
Study: 22217192
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/Losartan 50 mg
Study: 22217192
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg/Losartan 50 mg
Study: 22217192
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/Losartan 100 mg
Study: 22217192
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg/Losartan 100 mg
Study: 22217192
Drug: Amlodipine camsylate/Losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine camsylate/Losartan 5 mg/50 mg
Study: 22217192
Drug: Amlodipine camsylate/Losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine camsylate/Losartan 5 mg/100 mg
Study: 22217192
Drug: Amlodipine camsylate/Losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine camsylate/Losartan 10 mg/50 mg
Study: 22217192
Drug: Amlodipine camsylate/Losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine camsylate/Losartan 10 mg/100 mg
Study: 16259286
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of dietary calcium plus physical activity 30 minutes three times per week
Study: 16259286
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of calcium citrate plus 500 mg of dietary calcium and physical activity three times per week
Study: 7479227
Drug: Hemodialysis (HD)
Normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hemodialysis (HD) treatment using cuprophan dialyzers and acetate containing solution (35 mEq/l), 4 hours, 3 times weekly.
Study: 7479227
Drug: Hemodialysis (HD)
Normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hemodialysis (HD) treatment (group I with hypotensive episodes).
Study: 7479227
Drug: Hemodialysis (HD)
Normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hemodialysis (HD) treatment (group II without hypotensive episodes).
Study: 19303012
Drug: Budesonide (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (9 mg/d) for 6 weeks
Study: 19303012
Drug: Open-label budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Open-label budesonide (9 mg/d) for 6 additional weeks after placebo
Study: 3418376
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no BCG therapy)
Study: 28318077
Drug: No sound
Approvals — FDA: no, EMA: no, PMDA: no
Description: No sound therapy intervention (Control)
Study: 26024727
Drug: Lenalidomide 10
Normalized name: lenalidomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 10 mg/day for 9 days
Study: 23011321
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg FC + hCRH
Study: 23011321
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg FC + hCRH
Study: 23011321
Drug: 0.075 mg
Normalized name: mestranol 0.075 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg FC + hCRH
Study: 23011321
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg FC + hCRH
Study: 23011321
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg FC + placebo
Study: 23011321
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg FC + placebo
Study: 23011321
Drug: 0.075 mg
Normalized name: mestranol 0.075 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg FC + placebo
Study: 23011321
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg FC + placebo
Study: 18261121
Drug: AstraTech implants
Normalized name: CATHETER,COUDE LOFRIC 10FR ASTRATECH #961040
Approvals — FDA: no, EMA: no, PMDA: no
Description: AstraTech implants
Study: 11029681
Drug: Antidepressants (tricyclics,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (tricyclics, selective serotonin reuptake inhibitors, S-adenosylmethionine)
Study: 8233289
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg BW IVIG
Study: 8233289
Drug: 0.8 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg BW IVIG
Study: 3157346
Drug: Aztreonam, 1
Normalized name: Aztreonam, 1 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam, 1 g intramuscularly
Study: 3157346
Drug: Spectinomycin, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectinomycin, 2 g intramuscularly
Study: 25269896
Drug: Platelet function
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet function monitoring guided antiplatelet therapy (adjusted aspirin to 200 mg/d if AA-induced IPA <50%, adjusted clopidogrel to 150 mg/d if ADP-induced IPA <30%)
Study: 25269896
Drug: Conventional dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dual antiplatelet therapy (standard treatment)
Study: 23217188
Drug: MAKS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAKS therapy (motor stimulation, practice of activities of daily living, cognitive stimulation), 2 hours, 6 days a week for 12 months.
Study: 29249224
Drug: MAKS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAKS therapy
Study: 23217188
Drug: MAKS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAKS therapy and Control group
Study: 18262450
Drug: Oxycodone-gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxycodone-gabapentin
Study: 15984630
Drug: Tazarotene cream
Normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene cream 0.05% and 0.1%
Study: 12906339
Drug: Monolithic osmotic
Normalized name: Ez2go Osmotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monolithic osmotic tablet system (MOTS) containing nifedipine, 30 mg
Study: 12906339
Drug: Commercial Adalat
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial Adalat osmotic tablet system containing nifedipine, 30 mg
Study: 1527273
Drug: Psychotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychotherapy without active medication
Study: 30783259
Drug: Fluoxetine (oral)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (oral) for 3 months
Study: 22694905
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy plus D-cycloserine (DCS)
Study: 22694905
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy plus placebo
Study: 18648963
Drug: Acupuncture (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (twice weekly for 6 weeks)
Study: 8517172
Drug: 5‐HT reuptake
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT reuptake inhibitors
Study: 2948737
Drug: Methoxamine infusion
Normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methoxamine infusion
Study: 2948737
Drug: Thymoxamine infusion
Normalized name: thymoxamine hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoxamine infusion
Study: 20691795
Drug: Disease-modifying anti-rheumatic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying anti-rheumatic drug treatment
Study: 18647806
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pegvisomant (PEG‐V)
Study: 31961448
Drug: Thresholds of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thresholds of TNE identified from compliant groups at each dose level
Study: 30488542
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg weekly for 16 weeks
Study: 29430253
Drug: High-dose Shen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Shen Guo Lao Nian Granule (SGLNG)
Study: 29430253
Drug: Middle-dose Shen
Normalized name: wheat middlings extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle-dose Shen Guo Lao Nian Granule (SGLNG)
Study: 29430253
Drug: Low-dose Shen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Shen Guo Lao Nian Granule (SGLNG)
Study: 23988786
Drug: 2.3 mg
Normalized name: menthol 2.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.3 mg kg(‐1) body mass of pseudoephedrine
Study: 23988786
Drug: 2.8 mg
Normalized name: pectin 2.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.8 mg kg(‐1) body mass of pseudoephedrine
Study: 10493678
Drug: Anti-19 kDa
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anti-19 kDa IgG antibodies
Study: 10493678
Drug: Anti-19 kDa
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anti-19 kDa IgA antibodies
Study: 10493678
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies to Yersinia outer membrane protein (YOP)
Study: 10493678
Drug: IgA antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgA antibodies to YOP
Study: 1912887
Drug: Amoxycillin 125
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 125 mg three times a day for seven days
Study: 6348658
Drug: Tinidazole IV
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tinidazole IV (1.60 g in 24 h)
Study: 6348658
Drug: Ornidazole IV
Normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornidazole IV (4 g in 4 days)
Study: 26068295
Drug: Denosumab treatment
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab treatment for 4 years
Study: 26068295
Drug: Denosumab treatment
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab treatment for 7 years
Study: 22841653
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 95% tricholoroacetic acid after dilatation and curettage
Study: 15378664
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba 240 mg daily
Study: 11548847
Drug: Post-APBSCT rhG-CSF
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-APBSCT rhG-CSF administration (Group B and C)
Study: 11548847
Drug: No rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: No rhG-CSF administration (Group A)
Study: 9740345
Drug: Unfractionated heparin/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated heparin/placebo
Study: 26678636
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose edoxaban (60mg/30mg dose reduced)
Study: 26678636
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose edoxaban (30mg/15mg dose reduced)
Study: 21917021
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg naftopidil daily
Study: 21917021
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg silodosin daily
Study: 18709689
Drug: Oral dehydroepiandrosterone
Normalized name: DEHYDROEPIANDROSTERONE
DrugBank: Prasterone sulfate (DB05804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dehydroepiandrosterone (DHEA) treatment (50 mg/day)
Study: 18709689
Drug: DHEA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA treatment in vitro
Study: 12875613
Drug: galantamine 24
Normalized name: galantamine 24 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: galantamine 24 mg/day
Study: 1653139
Drug: Sumatriptan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (100 mg dispersible tablet)
Study: 1653139
Drug: Cafergot (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cafergot (2 mg ergotamine tartrate, 200 mg caffeine)
Study: 24014554
Drug: Intensive chelation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chelation therapy
Study: 24014554
Drug: Ferritin levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferritin levels above 1800 G/L
Study: 17020163
Drug: Divator Drogsan
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divator Drogsan Pharmaceuticals (test formulation)
Study: 17020163
Drug: Lipitor (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipitor (reference formulation)
Study: 15022654
Drug: Traditional Ayurvedic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional Ayurvedic supplement
Study: 10859081
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of intravenous ketorolac at the onset of the procedure (Group B)
Study: 10859081
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of ketorolac mixed with local anesthetic (Group C)
Study: 10859081
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) injections (Group A)
Study: 8459068
Drug: Intravenous Solu‐Medrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Solu‐Medrol (1,000 mg for 3 days)
Study: 8459068
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (100 mg bolus for 3 days, tapering over 14 days)
Study: 8459068
Drug: Intravenous Solu‐Medrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Solu‐Medrol
Study: 3541604
Drug: Oral influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral influenza vaccine (killed vaccine, 98 ug hemagglutinin of A/Bangkok)
Study: 3541604
Drug: Intramuscular influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular influenza vaccine
Study: 29583015
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day resveratrol
Study: 12788893
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) infusion at a rate to raise local GH to approximately 40 ng/ml for 4 hours
Study: 12466370
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) infusion
Study: 10657837
Drug: Abnormal pattern
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abnormal pattern of urinary excretion of LTB(4) and its metabolites
Study: 3899818
Drug: Neutral human
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral human insulin (0.3 U/kg)
Study: 3899818
Drug: Acid bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acid bovine soluble insulin (0.3 U/kg)
Study: 3899818
Drug: Moderate antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate antibody levels
Study: 3899818
Drug: Acid bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acid bovine soluble insulin
Study: 3899818
Drug: Neutral human
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral human insulin
Study: 21998076
Drug: Methylnaltrexone 12
Normalized name: methylnaltrexone 12 mg/0.6 mL subcutaneous kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylnaltrexone 12 mg
Study: 25438529
Drug: High-dose milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose milk powder (55g daily)
Study: 25438529
Drug: Low-dose milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose milk powder (33g daily)
Study: 21711525
Drug: Action‐Observation Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action‐Observation Therapy (UP‐CAT)
Study: 16107949
Drug: Recombinant glycoprotein
Normalized name: Recombinant glycoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant glycoprotein 120 vaccine
Study: 3179151
Drug: 0.75% 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% 10 ml (75 mg)
Study: 3179151
Drug: 0.5% 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% 15 ml (75 mg)
Study: 3179151
Drug: 0.75% 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% 15 ml (112.5 mg)
Study: 3179151
Drug: 0.75% 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% 10 ml (75 mg) in patients older than 50 years
Study: 3179151
Drug: 0.75% 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% 15 ml (75 mg) in patients older than 50 years
Study: 30883861
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitor
Study: 27402210
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (10 treatments)
Study: 27402210
Drug: Shock wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock wave therapy (4 treatments)
Study: 23469593
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Domperidone or Esomeprazole)
Study: 17618958
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg Rhodiola rosea per day for 4 days
Study: 16356089
Drug: TPOAb positive
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPOAb positive (TPOAb(+) > 100 U/ml)
Study: 16356089
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of thyroid medication
Study: 11940309
Drug: Ramipril treatment
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril treatment (n = 21)
Study: 8594697
Drug: Single-dose diethylcarbamazine
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose diethylcarbamazine (DEC) 6mg/kg
Study: 8594697
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of 6 doses (total 36 mg/kg) of DEC
Study: 2569857
Drug: Dilevalol 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol 200 mg qd
Study: 2569857
Drug: Captopril 100
Normalized name: captopril 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 100 mg bid
Study: 2569857
Drug: Nifedipine 40
Normalized name: nifedipine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 40 mg bid
Study: 28431589
Drug: Albendazole plus
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole plus antiepileptic drugs
Study: 28431589
Drug: Antiepileptic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic treatment (Control)
Study: 16995457
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic prophylaxis (group II)
Study: 15298069
Drug: Olcegepant, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olcegepant, a non-peptide CGRP receptor antagonist, details on dosage and duration not available
Study: 11147785
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g daily during immobilization, 15 g daily during first 3 weeks of rehabilitation, 5 g daily during last 7 weeks of rehabilitation)
Study: 31473867
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) twice weekly for 6 weeks
Study: 20694481
Drug: Remifentanil (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (group R) used in combination with fentanyl as intravenous analgesic.
Study: 20694481
Drug: Fentanyl alone
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl alone (group C) as intravenous analgesic.
Study: 12579093
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (cisplatin at 80 mg/m(2) on 1 day and vindesine at 3 mg/m(2) on 2 days) followed by surgery
Study: 1958276
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (CyA, Aza, MP)
Study: 1958276
Drug: Triple therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy, Aza + CyA, CyA + MP